Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

DT-216P2

Gene therapy · developed by Design Therapeutics

Phase 1/2 Most advanced trial
DSGN Developer
1 Registered trials

What is DT-216P2?

DT-216P2 is a gene therapy that delivers a functional copy of the FXN gene, which encodes frataxin, a mitochondrial protein whose deficiency underlies Friedreich ataxia. It is studied in Friedreich ataxia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Therapy area
Neurology
Developer
Design Therapeutics, Inc. (DSGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06874010 Phase 1/2 Friedreich Ataxia Recruiting DSGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Friedreich Ataxia

More from Design Therapeutics

DT-168 Phase 2 DT-216 Phase 1

Follow DSGN, the company behind DT-216P2

See DSGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DSGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.